I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: August 25, 2011

Electronic Signature for Amy E. Mandragouras, Esq.: /Amy E. Mandragouras,

Fea /

Docket No.: SYNI-003CNRCE2 (PATENT)

Examiner: N. Archie

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Gerald Walter Fischer *et al.*

Application No.: 10/601,171 Confirmation No.: 4940

Filed: June 23, 2003 Art Unit: 1645

For: OPSONIC AND PROTECTIVE

MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR

LIPOTEICHOIC ACID OF GRAM POSITIVE

BACTERIA

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of the following document, cited in a European Office Action issued July 4, 2011, during the prosecution of Application No. 10182580.0, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submits this document for the Examiner's consideration. This document is cited on the enclosed PTO Form SB/08, and a copy of the European Office Action as required under 37 CFR 1.98(a)(2) is also enclosed.

Application No.: 10/601,171 Docket No.: SYNI-003CNRCE2

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. SYNI-003CNRCE2.

Dated: August 25, 2011 Respectfully submitted,

Electronic signature: /Amy E. Mandragouras,

M/mch Esq./

Amy E. Mandragouras, Esq. Registration No.: 36,207

NELSON MULLINS RILEY & SCARBOROUGH LLP

One Post Office Square Boston, Massachusetts 02109-2127

(800) 237-2000

(617) 742-4214 (Fax)

Attorney/Agent For Applicants